Skye Bioscience, Inc.SKYENASDAQ
Loading
SG&A Expenses Over TimeContracting
Percentile Rank92
3Y CAGR+37.4%
5Y CAGR+29.5%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+37.4%/yr
vs +8.7%/yr prior
5Y CAGR
+29.5%/yr
Recent acceleration
Acceleration
+28.7pp
Accelerating
Percentile
P92
Near historical high
vs 5Y Ago
3.6x
Strong expansion
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$15.80M-10.9%
2024$17.73M+125.7%
2023$7.85M+28.8%
2022$6.09M+24.0%
2021$4.92M+13.1%
2020$4.34M-1.1%
2019$4.39M+0.7%
2018$4.36M+23.0%
2017$3.55M+0.5%
2016$3.53M-